527 related articles for article (PubMed ID: 19483646)
1. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ
J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma.
Lutzky J; Weber R; Nunez Y; Gillett M; Spitler L
J Immunother; 2009 Jan; 32(1):79-85. PubMed ID: 19307996
[TBL] [Abstract][Full Text] [Related]
3. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
5. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
; Celis E
Cancer; 2007 Jul; 110(1):203-14. PubMed ID: 17541944
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.
Daud AI; Mirza N; Lenox B; Andrews S; Urbas P; Gao GX; Lee JH; Sondak VK; Riker AI; Deconti RC; Gabrilovich D
J Clin Oncol; 2008 Jul; 26(19):3235-41. PubMed ID: 18591558
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor.
Spitler LE; Grossbard ML; Ernstoff MS; Silver G; Jacobs M; Hayes FA; Soong SJ
J Clin Oncol; 2000 Apr; 18(8):1614-21. PubMed ID: 10764421
[TBL] [Abstract][Full Text] [Related]
8. Sequential administration of GM-CSF (Sargramostim) and IL-2 +/- autologous vaccine as adjuvant therapy in cutaneous melanoma: an interim report of a phase II clinical trial.
Elias EG; Zapas JL; McCarron EC; Beam SL; Hasskamp JH; Culpepper WJ
Cancer Biother Radiopharm; 2008 Jun; 23(3):285-91. PubMed ID: 18593361
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients.
Barrio MM; de Motta PT; Kaplan J; von Euw EM; Bravo AI; Chacón RD; Mordoh J
J Immunother; 2006; 29(4):444-54. PubMed ID: 16799340
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
[TBL] [Abstract][Full Text] [Related]
11. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
[TBL] [Abstract][Full Text] [Related]
12. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor.
Rini BI; Fong L; Weinberg V; Kavanaugh B; Small EJ
J Urol; 2006 Jun; 175(6):2087-91. PubMed ID: 16697809
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
[TBL] [Abstract][Full Text] [Related]
14. Individualized synthetic peptide vaccines with GM-CSF in locally advanced melanoma patients.
Atzpodien J; Fluck M; Reitz M
Cancer Biother Radiopharm; 2004 Dec; 19(6):758-63. PubMed ID: 15665624
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma.
Mastrangelo MJ; Maguire HC; Eisenlohr LC; Laughlin CE; Monken CE; McCue PA; Kovatich AJ; Lattime EC
Cancer Gene Ther; 1999; 6(5):409-22. PubMed ID: 10505851
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
[TBL] [Abstract][Full Text] [Related]
17. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
[TBL] [Abstract][Full Text] [Related]
18. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
[TBL] [Abstract][Full Text] [Related]
19. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
Mikysková R; Indrová M; Símová J; Jandlová T; Bieblová J; Jinoch P; Bubeník J; Vonka V
Int J Oncol; 2004 Jan; 24(1):161-7. PubMed ID: 14654953
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial.
Ravaud A; Delaunay M; Chevreau C; Coulon V; Debled M; Bret-Dibat C; Courbon F; Gualde N; Nguyen Bui B
Br J Cancer; 2001 Nov; 85(10):1467-71. PubMed ID: 11720430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]